If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

Patrick Payne, a Group 1-winning trainer, has been charged by Racing Victoria (RV) stewards after presenting a horse to the ...

Trainer to face charges for presenting horse to the races twice in 2024 with several banned substances in his system ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The ...

Objective: To assess the genotypic and allelic distribution of the rs10046 polymorphism in the CYP19A1 gene and evaluate whether this aromatase gene variant is associated with cardiovascular risk in ...

内分泌治疗是激素受体阳性（HR+）乳腺癌初始治疗的基石，然而耐药问题无可避免。尽管近年来 CDK4/6 抑制剂能够有效克服内分泌耐药，但仍有部分人群对 CDK4/6 抑制剂治疗效果不佳或不耐受。因此，寻找新的联合治疗策略仍是临床亟待解决的重点难点。

Stargate will build “the physical and virtual infrastructure to power the next generation of AI,” including data centers around the country, Trump said. Ellison said the group’s first ...